Celltrion has pushed forward with plans to bring its novel subcutaneous version of infliximab to the US market, even if it means having to file the product via a standalone biologics license application rather than as a biosimilar.
The Korean firm’s CT-P13 subcutaneous infliximab product – marketed in other territories as Remsima SC, an innovative variant of its...






